Clinical trial · Observational
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
NCT06782789CI-TRIAL-00084884TALOsrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is pilot, observational, retrospective, Italian multicenter study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall response rate (ORR)
- timeFrame
- through study completion, an average of 2 years
- description
- ORR as the sum of complete response \[CR\] and partial response \[PR\] rate. The study aims to retrospectively evaluate the effectiveness of tafasitamab in association with lenalidomide in patients with R/R DLBCL treated with at least one dose of tafasitamab in association with lenalidomide under the NPP.
Secondary outcomes (6)
- measure
- Duration of Response (DoR)
- timeFrame
- through study completion, an average of 2 years
- description
- the secondary aim is to evaluate effectiveness of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017)
- measure
- Toxicity of study drug
- timeFrame
- from enrollment untill 30 days from last infusion
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed diagnosis of R/R DLBCL. 2. Patientswho received at least one dose of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017), between April 2022 and December 2022. 3. Age ≥ 18 years at enrollment. 4. Signature of written informed consent (if applicable). Exclusion Criteria: 1\) R/R DLBCL patients who received tafasitamab in association with lenalidomide in a clinical trial context.
References
Publications (0)
Data not yet available
No reference posted for this study.